NSCs of the SEZ are considered glioma cells of origin [62, 63], and molecular alterations of the EGFR/PI3K/AKT/mTOR module are hallmarks of this cancer type, which has led to the design of clinical trials devised to target this pathway [64]. The gene discussed is MTOR; the disease is glioma.